<DOC>
	<DOCNO>NCT00077168</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether radiation therapy surgery effective prevent recurrence ductal carcinoma situ . PURPOSE : This randomized phase II trial study adjuvant radiation therapy see well work compare observation surgery treat woman estrogen receptor positive progesterone receptor positive ductal carcinoma situ also receive either tamoxifen anastrozole .</brief_summary>
	<brief_title>Adjuvant Radiation Therapy Compared With Observation After Surgery Treating Women With Estrogen Receptor Positive Progesterone Receptor Positive Ductal Carcinoma In Situ Breast Who Are Receiving Tamoxifen Anastrozole</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare ipsilateral tumor relapse breast cancer metastases woman completely excise low-risk estrogen receptor- progesterone receptor-positive ductal carcinoma situ breast receive adjuvant tamoxifen anastrozole treat adjuvant radiotherapy v observation alone . - Compare quality life patient treat regimen . Secondary - Determine minimal surgical margin require minimize local recurrence rate patient treat regimen . - Identify molecular marker predict ipsilateral tumor recurrence patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center . Patients randomize 1 2 treatment arm . All patient receive adjuvant tamoxifen anastrozole 5 year . - Arm I : Patients undergo radiotherapy 5 day week 3 5 week . - Arm II : Patients undergo observation alone . Quality life assess baseline , 6 month , 1 , 2 , 5 year . Patients follow every 6 month 1 year annually 10 year . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 2,000 patient ( 1,000 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis unifocal ductal carcinoma situ breast without invasive component Microinvasion ( define 1 foci invasion &lt; 1 mm ) allow Prior complete microscopic excision ( within past 6 month ) minimum radial margin 1 mm specimen xray require Maximum microscopic tumor diameter &lt; 30 mm ( &lt; 15 mm grade 3 tumor ) Planning receive adjuvant tamoxifen anastrozole 5 year Eligible patient may receive adjuvant endocrine therapy ICRIBISII Hormone receptor status : Estrogen receptor positive OR Progesterone receptor positive More 10 % tumor stain receptor OR cutpoint â‰¥ 2 PATIENT CHARACTERISTICS : Sex Female Menopausal status Premenopausal , perimenopausal , postmenopausal Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No prior deep vein thrombosis Pulmonary No prior pulmonary embolus Other No unexplained postmenopausal bleed No contraindication fulldose radiotherapy breast No cancer within past 5 year except nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy See Disease Characteristics No prior tamoxifen raloxifene use 3 month duration Radiotherapy Not specify Surgery See Disease Characteristics No prior mastectomy Other No concurrent anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>